uk 68798 has been researched along with terfenadine in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 14 (50.00) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
| Keserü, GM | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brown, AM; Dennis, A; Rampe, D; Roy, ML | 1 |
| Tytgat, J; Ulens, C | 1 |
| Annunziato, L; Cataldi, M; Di Renzo, G; Giorgio, G; Secondo, A; Taglialatela, M; Valore, M | 1 |
| Finlayson, K; January, CT; Kelly, JS; Sharkey, J; Turnbull, L | 1 |
| Hashimoto, K; Miyata, K; Nakamura, Y; Sato, S; Satoh, Y; Shimizu-Sasamata, M; Sugiyama, A; Takahara, A | 1 |
| Dong, DL; Du, ZM; Li, Z; Wang, HZ; Xu, CQ; Xu, DH; Yang, BF | 1 |
| Cox, BF; Gintant, GA; Limberis, JT; Martin, RL; Su, Z | 1 |
| Clozel, M; Hess, P; Rey, M; Steiner, B; Wanner, D | 1 |
| Friemel, A; Zünkler, BJ | 1 |
| Cox, BF; Diaz, GJ; Gintant, GA; Houseman, K; Limberis, JT; Liu, X; Martin, RL; Su, Z | 1 |
| Brandenburger, M; Grunow, B; Mehnert, JM | 1 |
| Clancy, CE; Romero, L; Saiz, J; Trenor, B; Yang, PC | 1 |
| Árpádffy-Lovas, T; Gazdag, P; Geramipour, A; Jost, N; Kohajda, Z; Orvos, P; Szlovák, J; Tálosi, L; Tóth, D; Varró, A; Virág, L | 1 |
| Claydon, TW; Genge, CE; Gunawan, M; Hobbs, Y; Hull, CM; Lin, E; Rayani, K; Shafaattalab, S; Tibbits, GF | 1 |
| Becker, N; Brinkwirth, N; Doi, M; Fertig, N; Friis, S; Furukawa, H; Hasegawa, Y; Obergrussberger, A; Ohtsuki, A; Oka, T; Stoelzle-Feix, S; Takasuna, K | 1 |
28 other study(ies) available for uk 68798 and terfenadine
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Topics: Arrhythmias, Cardiac; Cation Transport Proteins; Cell Line; Cisapride; DNA-Binding Proteins; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart; Humans; Kv1.5 Potassium Channel; Myocardium; Patch-Clamp Techniques; Phenethylamines; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Tumor Cells, Cultured | 1997 |
Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation.
Topics: Animals; Astemizole; Cation Transport Proteins; DNA-Binding Proteins; Electric Conductivity; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Gene Expression; Humans; Microelectrodes; Mutation; Oocytes; Oxidation-Reduction; Patch-Clamp Techniques; Phenethylamines; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Xenopus | 2000 |
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.
Topics: Animals; Anti-Arrhythmia Agents; Astemizole; Biological Transport; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cation Transport Proteins; Cells, Cultured; Cetirizine; Electrophysiology; Ether-A-Go-Go Potassium Channels; Histamine H1 Antagonists; Hydroxyzine; Large-Conductance Calcium-Activated Potassium Channels; Nimodipine; Phenethylamines; Pituitary Gland; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Calcium-Activated; Potassium Channels, Voltage-Gated; Rats; Small-Conductance Calcium-Activated Potassium Channels; Sulfonamides; Terfenadine | 2000 |
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
Topics: Anti-Arrhythmia Agents; Benzimidazoles; Binding, Competitive; Cation Transport Proteins; Cell Line; Cell Membrane; DNA-Binding Proteins; Drug Evaluation, Preclinical; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Patch-Clamp Techniques; Phenethylamines; Pimozide; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Sulfanilamides; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Tritium | 2001 |
Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.
Topics: Action Potentials; Animals; Cation Transport Proteins; Cell Line; DNA-Binding Proteins; Dogs; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Famotidine; Guinea Pigs; Heart Block; Hemodynamics; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; In Vitro Techniques; Long QT Syndrome; Papillary Muscles; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Torsades de Pointes; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Topics: Animals; Anti-Allergic Agents; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Ganglionic Stimulants; Ion Channel Gating; Mutation; Nicotine; Oocytes; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinidine; Sulfonamides; Terfenadine; Xenopus laevis | 2004 |
Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Topics: Cell Line; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Kidney; Mesoridazine; Phenethylamines; Potassium; Potassium Channel Blockers; Quinidine; Sulfonamides; Terfenadine | 2006 |
Measurements of blood pressure and electrocardiogram in conscious freely moving guineapigs: a model for screening QT interval prolongation effects.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Electrocardiography; Enalapril; Guinea Pigs; Heart Rate; Histamine H1 Antagonists, Non-Sedating; Male; Models, Animal; Phenethylamines; Sotalol; Sulfonamides; Telemetry; Terfenadine | 2007 |
Interactions at human ether-à-go-go-related gene channels.
Topics: Binding Sites; Cell Line; Chlorobutanol; Drug Combinations; Drug Synergism; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluvoxamine; Histamine H1 Antagonists, Non-Sedating; Humans; Kidney; Patch-Clamp Techniques; Phenethylamines; Scorpion Venoms; Sulfonamides; Terfenadine | 2010 |
Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.
Topics: Acetates; Analysis of Variance; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Patch-Clamp Techniques; Phenethylamines; Pyrazoles; Sotalol; Sulfonamides; Terfenadine; Tritium | 2012 |
Electrophysiological characterization of spontaneously contracting cell aggregates obtained from rainbow trout larvae with multielectrode arrays.
Topics: Amino Acid Sequence; Animals; Cardiac Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fish Proteins; Heart; Humans; Larva; Molecular Sequence Data; Myocardium; Oncorhynchus mykiss; Phenethylamines; Potassium Channel Blockers; Sequence Homology, Amino Acid; Sulfonamides; Terfenadine | 2013 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expression; Genetic Predisposition to Disease; Heart Ventricles; Humans; Ion Channel Gating; Kinetics; Long QT Syndrome; Models, Statistical; Mutation; Phenethylamines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Conformation; Severity of Illness Index; Sotalol; Sulfonamides; Terfenadine | 2014 |
Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Female; Heart Ventricles; Humans; Ion Channels; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Rabbits; Sotalol; Sulfonamides; Terfenadine; Tissue Donors; Verapamil | 2019 |
Investigating the utility of adult zebrafish ex vivo whole hearts to pharmacologically screen hERG channel activator compounds.
Topics: Animals; Chlorobenzenes; Cresols; Ether-A-Go-Go Potassium Channels; Gene Expression Regulation; Heart; Histamine H1 Antagonists, Non-Sedating; Oocytes; ortho-Aminobenzoates; Phenethylamines; Phenylurea Compounds; Piperidines; Potassium Channel Blockers; Quinolines; Sulfonamides; Terfenadine; Xenopus laevis; Zebrafish; Zebrafish Proteins | 2019 |
Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.
Topics: Animals; Arrhythmias, Cardiac; Astemizole; Benchmarking; Calibration; Cardiovascular Agents; Cell Line; CHO Cells; Cricetulus; Drug Discovery; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Heart; HEK293 Cells; Humans; Patch-Clamp Techniques; Phenethylamines; Polypropylenes; Polytetrafluoroethylene; Reference Standards; Reproducibility of Results; Sulfonamides; Terfenadine | 2020 |